-
Publication Venue For
-
Targeted maximum likelihood estimation of causal effects with interference: A simulation study..
41:4554-4577.
2022
-
Constrained randomization and statistical inference for multi-arm parallel cluster randomized controlled trials..
41:1862-1883.
2022
-
Bayesian variable selection for understanding mixtures in environmental exposures..
40:4850-4871.
2021
-
Propensity score weighting for causal subgroup analysis..
40:4294-4309.
2021
-
Propensity score weighting for covariate adjustment in randomized clinical trials..
40:842-858.
2021
-
Simultaneous record linkage and causal inference with propensity score subclassification..
37:3533-3546.
2018
-
Identifying optimal dosage regimes under safety constraints: An application to long term opioid treatment of chronic pain..
37:1407-1418.
2018
-
Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks..
37:1389-1401.
2018
-
Accommodating the ecological fallacy in disease mapping in the absence of individual exposures..
36:4930-4942.
2017
-
Bayesian multinomial probit modeling of daily windows of susceptibility for maternal PM2.5 exposure and congenital heart defects..
35:2786-2801.
2016
-
Multiple imputation for harmonizing longitudinal non-commensurate measures in individual participant data meta-analysis..
34:3399-3414.
2015
-
A marginalized zero-inflated Poisson regression model with overall exposure effects..
33:5151-5165.
2014
-
Imputation of confidential data sets with spatial locations using disease mapping models..
33:1928-1945.
2014
-
Correction to How to interpret a small increase in AUC with an additional risk prediction marker: Decision analysis comes through [Statist. Med. (2015) 33, 22, 3946-3959] DOI: 10.1002/sim.6195.
34:900.
2014
-
A latent factor linear mixed model for high-dimensional longitudinal data analysis..
32:4229-4239.
2013
-
Propensity score weighting with multilevel data..
32:3373-3387.
2013
-
Phase II clinical trials with time-to-event endpoints: Optimal two-stage designs with one-sample log-rank test
2013
-
A spatio-temporal absorbing state model for disease and syndromic surveillance..
31:2123-2136.
2012
-
Sensitivity analysis for unmeasured confounding in principal stratification settings with binary variables..
31:949-962.
2012
-
Correction: Evaluation metrics for biostatistical and epidemiological collaborations.
31:600.
2012
-
Authors' reply.
31:96-97.
2012
-
A min-max combination of biomarkers to improve diagnostic accuracy.
30:3266.
2011
-
The end of the beginning: A commentary on 'Evaluation metrics for biostatistical and epidemiological collaborations': A rejoinder.
30:2783-2784.
2011
-
Hierarchical spatial modeling of uncertainty in air pollution and birth weight study..
30:2187-2198.
2011
-
Estimating propensity scores with missing covariate data using general location mixture models..
30:627-641.
2011
-
Comparative effectiveness research: Policy context, methods development and research infrastructure..
29:1963-1976.
2010
-
Joint Bayesian analysis of birthweight and censored gestational age using finite mixture models..
29:1710-1723.
2010
-
A bivariate survival model with compound Poisson frailty..
29:275-283.
2010
-
A robust method for comparing two treatments in a confirmatory clinical trial via multivariate time-to-event methods that jointly incorporate information from longitudinal and time-to-event data..
29:75-85.
2010
-
Response to ‘Net reclassification improvement and decision theory’ by Vickers et al
..
28:526-528.
2009
-
Semiparametric Bayesian modeling of random genetic effects in family-based association studies..
28:113-139.
2009
-
'Smooth' inference for survival functions with arbitrarily censored data..
27:5421-5439.
2008
-
Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology..
27:5525-5555.
2008
-
Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach..
27:4658-4677.
2008
-
A distribution-free test of constant mean in linear mixed effects models..
27:3833-3846.
2008
-
Estimation of propensity scores using generalized additive models..
27:3805-3816.
2008
-
Sample size calculation for the weighted rank statistics with paired survival data..
27:3350-3365.
2008
-
Joint modeling of sensitivity and specificity..
27:1745-1761.
2008
-
Age-specific prevalence and years of healthy life in a system with three health states..
27:1371-1386.
2008
-
Randomized phase II trials with a prospective control..
27:568-583.
2008
-
Comments on 'Integrated discrimination and net reclassification improvements - Practical advice'.
27:207-212.
2008
-
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond..
27:157-172.
2008
-
Relative quantification based on logistic models for individual polymerase chain reactions..
26:5596-5611.
2007
-
Morphometric analysis for early detection of changes in cellular structure in a toxicological experiment..
26:5253-5266.
2007
-
A correlated frailty model with long-term survivors for estimating the heritability of breast cancer..
26:3722-3734.
2007
-
Analysis on binary responses with ordered covariates and missing data..
26:3443-3458.
2007
-
Bayesian methods for searching for optimal rules for timing intercourse to achieve pregnancy..
26:1920-1936.
2007
-
Stability analysis for drugs with multiple active ingredients..
26:1512-1517.
2007
-
Bivariate random effect model using skew-normal distribution with application to HIV-RNA..
26:1255-1267.
2007
-
Choice of time scale and its effect on significance of predictors in longitudinal studies..
26:1343-1359.
2007
-
Performance assessment for radiologists interpreting screening mammography..
26:1532-1551.
2007
-
Inference for case-control studies when exposure status is both informatively missing and misclassified..
25:4065-4080.
2006
-
Bayesian semi-parametric ROC analysis..
25:3905-3928.
2006
-
Estimating measures of diagnostic accuracy when some covariate information is missing..
25:2981-2993.
2006
-
Interval estimation for treatment effects using propensity score matching..
25:2230-2256.
2006
-
Author's reply [4].
25:1437-1438.
2006
-
On non-inferiority margin and statistical tests in active control trials..
25:1101-1113.
2006
-
Rank tests for clustered survival data when dependent subunits are randomized..
25:361-373.
2006
-
Examining accuracy of screening mammography using an event order model..
25:267-283.
2006
-
Assay validation for left-censored data..
24:3347-3360.
2005
-
A multiple testing procedure to associate gene expression levels with survival..
24:3077-3088.
2005
-
Sample size for a two-group comparison of repeated binary measurements using GEE..
24:2583-2596.
2005
-
Statistical inference for cancer trials with treatment switching..
24:1783-1790.
2005
-
Assessing intra, inter and total agreement with replicated readings..
24:1371-1384.
2005
-
A practical approach for comparing means of two groups without equal variance assumption: H. Wang and S. Chow, Statistics in Medicine 2002; 21:3137-3151..
24:817-818.
2005
-
Analysis of clinical data with breached blindness: by Shein-Chung Chow and Jun Shao Statistics in Medicine 2004; 23:1185-1193..
24:819-821.
2005
-
Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study..
23:2937-2960.
2004
-
Strength of accumulating evidence and data monitoring committee decision making..
23:2659-2672.
2004
-
Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation..
23:2109-2123.
2004
-
Sample size determination for comparing several survival curves with unequal allocations..
23:1793-1815.
2004
-
Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?.
23:1503-1505.
2004
-
Analysis of clinical data with breached blindness..
23:1185-1193.
2004
-
On the estimation of the binomial probability in multistage clinical trials..
23:881-896.
2004
-
Admissible two-stage designs for phase II cancer clinical trials..
23:561-569.
2004
-
Growth velocity assessment in paediatric AIDS: smoothing, penalized quantile regression and the definition of growth failure..
23:509-526.
2004
-
The heritability of cause-specific mortality: a correlated gamma-frailty model applied to mortality due to respiratory diseases in Danish twins born 1870-1930..
22:3873-3887.
2003
-
ROC methodology within a monitoring framework..
22:3473-3488.
2003
-
A global sensitivity analysis of performance of a medical diagnostic test when verification bias is present..
22:2711-2721.
2003
-
Evaluating medical diagnostic tests at the subunit level in the presence of verification bias..
22:2161-2176.
2003
-
Power calculations for large multi-arm placebo-controlled studies of dichotomous outcomes..
22:1943-1954.
2003
-
Estimating correlation by using a general linear mixed model: evaluation of the relationship between the concentration of HIV-1 RNA in blood and semen..
22:1457-1464.
2003
-
Sample size estimation for GEE method for comparing slopes in repeated measurements data..
22:1305-1315.
2003
-
Missing data in the 2 x 2 table: patterns and likelihood-based analysis for cross-sectional studies with supplemental sampling..
22:517-534.
2003
-
A parametric model for long-term follow-up data from phase III breast cancer clinical trials..
22:339-352.
2003
-
In vitro bioequivalence testing..
22:55-68.
2003
-
A practical approach for comparing means of two groups without equal variance assumption..
21:3137-3151.
2002
-
The ebb and flow of the NHS waiting list: how do recruitment and admission affect event-based measures of the length of 'time-to-admission'?.
21:2991-3009.
2002
-
Industry perspectives on ICH guidelines..
21:2949-2957.
2002
-
A multistate model for the genetic analysis of the ageing process..
21:2511-2526.
2002
-
Reproducibility probability in clinical trials..
21:1727-1742.
2002
-
Individual bioequivalence testing under 2x3 designs..
21:629-648.
2002
-
The impact of the international guideline entitled Statistical Principles for Clinical Trials (ICH E9)..
20:2549-2560.
2001
-
Using observational data to estimate prognosis: an example using a coronary artery disease registry..
20:2505-2532.
2001
-
Evaluation of an adjusted chi-square statistic as applied to observational studies involving clustered binary data..
20:2149-2161.
2001
-
Sample size calculations for clustered binary data..
20:1971-1982.
2001
-
Two-phase shelf-life estimation..
20:1239-1248.
2001
-
Bayesian analyses of longitudinal binary data using Markov regression models of unknown order..
20:755-770.
2001
-
Tests for 2 x K contingency tables with clustered ordered categorical data..
20:785-794.
2001
-
Assessing human fertility using several markers of ovulation..
20:965-978.
2001
-
Detecting treatment-by-centre interaction in multi-centre clinical trials..
20:193-213.
2001
-
Strategic use of statistical thinking in drug development..
19:3211-3217.
2000
-
Preface. Bioequilavence measures..
19:2719.
2000
-
The bootstrap procedure in individual bioequivalence..
19:2741-2754.
2000
-
First steps in analysing NHS waiting times: avoiding the 'stationary and closed population' fallacy..
19:2037-2051.
2000
-
Modelling covariance structure in the analysis of repeated measures data..
19:1793-1819.
2000
-
On statistical analysis for placebo-challenging designs in clinical trials..
19:1029-1037.
2000
-
Comparison of diagnostic markers with repeated measurements: a non-parametric ROC curve approach..
19:511-523.
2000
-
Prognostic models based on literature and individual patient data in logistic regression analysis..
19:141-160.
2000
-
Accounting for unreported and missing intercourse in human fertility studies.
19:665-679.
2000
-
The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials..
18:3435-3451.
1999
-
Evaluating the exposure and disease relationship with adjustment for different types of exposure misclassification: a regression approach..
18:2795-2808.
1999
-
Testing proportionality in the proportional odds model fitted with GEE..
18:1419-1433.
1999
-
A regression model for multivariate random length data..
18:199-211.
1999
-
Combining classification trees using MLE.
18:727-740.
1999
-
The effects of measurement error in response variables and tests of association of explanatory variables in change models..
17:2597-2606.
1998
-
Comparing risk-adjustment methods for provider profiling..
16:2645-2664.
1997
-
Testing homogeneity of intra-run variance parameters in immunoassay..
16:1765-1776.
1997
-
Bayesian inference in two-phase prevalence studies..
16:1121-1133.
1997
-
Statistical methods for two-sequence three-period cross-over designs with incomplete data..
16:1031-1039.
1997
-
The impact of patient compliance on drug concentration profile in multiple doses..
15:659-669.
1996
-
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors..
15:361-387.
1996
-
A statistic for comparing two correlated markers which are prognostic for time to an event..
14:2217-2225.
1995
-
The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables..
14:2119-2129.
1995
-
Non-parametric estimation for the difference or ratio of median failure times for paired observations..
14:275-281.
1995
-
Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer..
13:1313-1327.
1994
-
The case against independent monitoring committees..
13:1411-1414.
1994
-
Assays for recombinant proteins: a problem in non-linear calibration..
13:1165-1179.
1994
-
Two-stage sampling in pharmaceutical applications..
12:1999-2008.
1993
-
A survey of monitoring practices in cancer clinical trials..
12:435-450.
1993
-
Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations..
12:471-479.
1993
-
DATA MONITORING AND INTERIM ANALYSES IN THE PHARMACEUTICAL-INDUSTRY - ETHICAL AND LOGISTICAL CONSIDERATIONS - MONITORING OF CLINICAL-TRIALS AND INTERIM ANALYSES FROM A DRUG SPONSORS POINT-OF-VIEW - DISCUSSION.
12:493-495.
1993
-
Discussion: Stephen George, a survey of monitoring practices in cancer clinical trials: Stephanie Green and John Crowley, data monitoring committees for Southwest Oncology Group clinical trials.
12:457-459.
1993
-
Analysing the relationship between change in a risk factor and risk of disease..
11:783-797.
1992
-
Test for batch-to-batch variation in stability analysis..
11:269-270.
1992
-
Correction: Outlier detection in bioavailability/bioequivalence studies (Statistics in Medicine (1990) 9 (549-558)).
11:425.
1992
-
On the estimation of total variability in assay validation..
10:1543-1553.
1991
-
Analyses of black and white differentials in the age trajectory of mortality in two closed cohort studies..
10:1043-1059.
1991
-
Methods for the analysis and assessment of clinical databases: the clinician's perspective..
10:617-628.
1991
-
Outlier detection in bioavailability/bioequivalence studies..
9:549-558.
1990
-
Test for batch-to-batch variation in stability analysis..
8:883-890.
1989
-
Commentary. Response to Dr Halperin on ‘models of the interaction of mortality and the evolution of risk factor distribution: A general stochastic process formulation’.
7:293-295.
1988
-
Estimating hidden morbidity via its effect on mortality and disability..
7:325-336.
1988
-
Models of the interaction of mortality and the evolution of risk factor distribution: a general stochastic process formulation..
7:239-256.
1988
-
The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model..
4:39-46.
1985
-
Regression modelling strategies for improved prognostic prediction..
3:143-152.
1984
-
Tying clinical research to patient care by use of an observational database..
3:375-387.
1984
-
Strategies for analysing ecological health data: models of the biological risk of individuals..
1:163-181.
1982
-
Discussion: Frank W Rockhold and G Enas, data monitoring and interim analyses in the pharmaceutical industry: Ethical and logistical considerations: George W Williams et al, monitoring of clinical trials and interim analyses from a drug sponsor's point of view
1993